KZIA ▲ +2.5% - Kazia Therapeutics Limited $KZIA KZIA KZIA - Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Kazia Therapeutics rose 2.5% following the release of preclinical data demonstrating that its drug candidate paxalisib can reprogram immunotherapy-resistant colorectal cancers and improve their response to immunotherapy treatment. The positive preclinical findings suggest a potential new therapeutic approach for a difficult-to-treat patient population, which supported investor optimism in the stock. 01-SEP-2026 07:30 AM ET